Health Care [ 3/12 ] | Pharmaceuticals [ 37/74 ]
NASDAQ | Common Stock
Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain.
Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.
The company is also developing three product candidates, including SP-102 (10 mg dexamethasone sodium phosphate viscous gel) (SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a Phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4% (SP-103), a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a Phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules) (SP-104), a novel low-dose delayed-release naltrexone hydrochloride, which has completed Phase 1 trials for the treatment of fibromyalgia.
The company has a collaboration with ACEA Therapeutics to Support the Expansion of ZTlido program.
Scilex Holding Company is headquartered in Palo Alto, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 28, 24 | -0.26 Decreased by -40.26% | -0.14 Decreased by -87.14% |
| May 13, 24 | -0.24 Decreased by -9.09% | -0.10 Decreased by -140.00% |
| Mar 12, 24 | -0.25 Decreased by -92.31% | -0.23 Decreased by -8.70% |
| Nov 13, 23 | -0.63 Decreased by -6.20 K% | -0.17 Decreased by -270.59% |
| Aug 30, 23 | -0.19 Decreased by -255.67% | - |
| May 12, 23 | -0.22 Decreased by -340.00% | - |
| Mar 7, 23 | -0.13 Decreased by -285.71% | - |
| Nov 4, 22 | -0.01 Increased by +87.50% | - |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 24 | 16.37 M Increased by +30.11% | -37.58 M Decreased by -41.03% | Decreased by -229.58% Decreased by -8.39% |
| Mar 31, 24 | 10.88 M Increased by +2.85% | -24.38 M Increased by +20.73% | Decreased by -223.97% Increased by +22.93% |
| Dec 31, 23 | 13.46 M Increased by +12.95% | -21.40 M Decreased by -19.66% | Decreased by -158.97% Decreased by -5.94% |
| Sep 30, 23 | 10.12 M Decreased by -11.07% | -35.53 M Decreased by -265.24% | Decreased by -351.18% Decreased by -285.82% |
| Jun 30, 23 | 12.58 M Increased by +58.74% | -26.65 M Decreased by -49.39% | Decreased by -211.80% Increased by +5.89% |
| Mar 31, 23 | 10.58 M Increased by +55.34% | -30.75 M Decreased by -236.36% | Decreased by -290.62% Decreased by -116.52% |
| Dec 31, 22 | 11.92 M Increased by +52.24% | -17.88 M Increased by +19.10% | Decreased by -150.05% Increased by +46.86% |
| Sep 30, 22 | 11.38 M Increased by +45.31% | 21.50 M Increased by +197.26% | Increased by +188.99% Increased by +166.93% |